Scholarlink

<p>Neonatal hypoxic-ischemic brain damage (HIBD) is a devastating disease for which no treatments that effectively mitigate severe neurological consequences exist. Recent studies have shown that costunolide (COS), a well-known bioactive sesquiterpene lactone, possesses potent anti-inflammatory and neuroprotective properties, but its efficacy in the context of HIBD remains unclear. Here, we investigated the neuroprotective effects of COS in both in vivo and in vitro models of hypoxic-ischemic (HI) brain injury. In vivo, we found that COS intervention following a HI event dramatically reduced the brain infarction volume, ameliorated the inflammatory response, promoted histological recovery, and improved the prognosis. To explore the underlying molecular mechanisms, we performed an in vitro study and reported that COS protected PC12 cells from oxygen‒glucose deprivation (OGD) insult by reducing the levels of inflammatory mediators. Furthermore, COS activated the PI3K/AKT signaling pathway to suppress NF-κB and inflammation. In contrast, the PI3K inhibitor LY294002 reversed these therapeutic benefits. Our findings reveal that COS is a promising neuroprotective agent and could be used to treat HIBD and other related brain injuries.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inhibition of Neuroinflammation by Costunolide Attenuates Hypoxic-Ischemic Brain Damage via the PI3K/AKT Pathway in Neonatal Rats

  • 期刊论文

  • 发表日期：

    2025年11月14日

查看全文
  • Yingying Hu,
  • Rengcheng Qian,
  • Yifeng He,
  • Qiqi Gao,
  • Xun Wang,
  • Huilin Lin,
  • Wei Lin,
  • Yu Fang,
  • Jianghu Zhu,
  • Xingyun Wang,
  • Yan Nan,
  • Zhenlang Lin

摘要

Neonatal hypoxic-ischemic brain damage (HIBD) is a devastating disease for which no treatments that effectively mitigate severe neurological consequences exist. Recent studies have shown that costunolide (COS), a well-known bioactive sesquiterpene lactone, possesses potent anti-inflammatory and neuroprotective properties, but its efficacy in the context of HIBD remains unclear. Here, we investigated the neuroprotective effects of COS in both in vivo and in vitro models of hypoxic-ischemic (HI) brain injury. In vivo, we found that COS intervention following a HI event dramatically reduced the brain infarction volume, ameliorated the inflammatory response, promoted histological recovery, and improved the prognosis. To explore the underlying molecular mechanisms, we performed an in vitro study and reported that COS protected PC12 cells from oxygen‒glucose deprivation (OGD) insult by reducing the levels of inflammatory mediators. Furthermore, COS activated the PI3K/AKT signaling pathway to suppress NF-κB and inflammation. In contrast, the PI3K inhibitor LY294002 reversed these therapeutic benefits. Our findings reveal that COS is a promising neuroprotective agent and could be used to treat HIBD and other related brain injuries.